News
Press ReleaseRevive Announces Closing of the Acquisition of Psilocin Pharma Corp.
TORONTO, March 05, 2020 - Revive Therapeutics Ltd. (“Revive” or the “Company”), a company focused on the research, development and commercialization of novel psychedelic and cannabinoid-based life sciences products, is pleased to announce that, further to its press...
Revive Provides Update on its Clinical Development Plan for Cannabidiol in the Treatment of Autoimmune Hepatitis
TORONTO, Feb. 18, 2020 - Revive Therapeutics Ltd. (“Revive” or the “Company”), a company focused on the research, development and commercialization of novel cannabinoid-based and life sciences products, is pleased to provide an update on the Company’s clinical...
Revive Enters into Psychedelics Market with Letter of Intent to Acquire Psilocin Pharma Corp.
TORONTO, Feb. 12, 2020 - Revive Therapeutics Ltd. (“Revive” or the “Company”) is pleased to announce that it has entered into a letter of intent, dated February 11, 2020 (the “LOI”) with Psilocin Pharma Corp. (“Psilocin”), an arm’s length party incorporated pursuant...
Revive Therapeutics Announces Brokered Private Placement of up to $2 million
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN TORONTO, Feb. 11, 2020 - Revive Therapeutics Ltd. (“Revive” or the “Company”), a cannabis life sciences company...
Revive Therapeutics to Pursue the Psychedelic Market With Agreement and Investment in Red Light Holland Financing
TORONTO, Feb. 10, 2020 - Revive Therapeutics Ltd. (“Revive”), a cannabis life sciences company focused on novel cannabinoid-based treatments for rare inflammatory diseases, is pleased to announce that it has entered into a supply and collaboration agreement (the...
Revive Therapeutics Announces Offering of $210,000 of Convertible Debenture Units
TORONTO, Feb. 05, 2020 - Revive Therapeutics Ltd. (“Revive”), a cannabis life sciences company focused on novel cannabinoid-based treatments for rare inflammatory diseases, is pleased to announce that it has issued 210,000 secured convertible debenture units (the...